Entheon Biomedical Corp. provide an update on its Observational Study, EBIQ-101. The results of EBIQ-101 will serve as the foundation for the strategic aims of Entheon IQTM and Entheon IDTM, the development of a framework for characterizing the psychedelic drug state of patients, and to research phenotypes associated with particular addictions and mental health disorders.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.15 CAD | 0.00% | -9.09% | +50.00% |
1st Jan change | Capi. | |
---|---|---|
+50.00% | 977K | |
+33.37% | 49.46B | |
+1.55% | 42.58B | |
+49.11% | 42.49B | |
-4.22% | 29.09B | |
+11.57% | 26.61B | |
-21.00% | 18.64B | |
+7.36% | 13.16B | |
+28.30% | 12.55B | |
+23.80% | 12.1B |
- Stock Market
- Equities
- ENBI Stock
- News Entheon Biomedical Corp.
- Entheon Biomedical Corp. Announces EBIQ-101 First-Patient Dose